OA
SUPN icon

OFI Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

OFI Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		$55K Sell
3,924
-1,181
-23% -$22K ﹤0.01% 1578
2015
Q2 		$87K Buy
+5,105
New +$72.7K 0.01% 1519

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OFI Advisors's SUPN Position: Q3 2015 in Review

OFI Advisors reduced its Supernus Pharmaceuticals (SUPN) stake by 23% in Q3 2015, selling an estimated $22K and leaving 3,924 shares worth $55K. The position accounts for ﹤0.01% of the portfolio, ranked #1578.

OFI Advisors first reported a position in SUPN in Q2 2015 and has held it in 2 quarters since. The position peaked at $87K in Q2 2015. 185 funds tracked by Wall St. Rank hold SUPN as of Q3 2015.

  • OFI Advisors held 3,924 shares of Supernus Pharmaceuticals worth $55K as of Q3 2015.
  • OFI Advisors sold 1,181 Supernus Pharmaceuticals shares in Q3 2015, an estimated $22K.
  • Supernus Pharmaceuticals made up ﹤0.01% of OFI Advisors's portfolio in Q3 2015, its #1578 holding.
  • OFI Advisors first reported a position in Supernus Pharmaceuticals in Q2 2015 and has held it in 2 quarters since.
  • OFI Advisors's Supernus Pharmaceuticals position peaked at $87K in Q2 2015.
  • 185 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2015.

Based on OFI Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.